Mayo Clinic Laboratories > Oncology > Lung cancer > Next-generation sequencing panel

Next-generation sequencing

Deepen understanding, optimize outcomes

Molecular testing is recommended for individuals with advanced lung cancer to identify genetic abnormalities that may predict response to targeted therapies. Optimized therapy selection in patients with lung cancer is critical to achieving the best outcomes.

Next-generation sequencing Test menu

Next-generation sequencing panels

Our targeted lung cancer panel assesses for mutations in 12 genes and rearrangements in seven genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK. The results of this panel ensure that physicians have the information they need to target therapy for their patient. This genetic information also can be useful in prognosis.

Our lung cancer-specific next-generation sequencing panel includes only clinically relevant markers, allowing for accurate and timely results. We have optimized specimen requirements by reducing the amount of formalin-fixed, paraffin-embedded (FFPE) tissue and accepting cytology, which allows more patients to receive results.

Key testing


Resistance mutation testing

Based on recently released guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology, patients in relapse after an initial response to EGFR-targeted therapies should be tested for the acquired T790M mutation in the EGFR gene.


Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.